George Golumbeski

George Golumbeski

Président chez SHATTUCK LABS, INC.

Fortune : 642 755 $ au 30/04/2024

67 ans
Health Technology
Commercial Services
Consumer Services

Profil

George S.
Golumbeski
is currently the Chairman at Carrick Therapeutics UK Ltd., Verseau Therapeutics, Inc., Actio Biosciences, Inc., Ananke Therapeutics, Inc., Shattuck Labs, Inc., Carrick Therapeutics Ltd., SAGE Therapeutics, Inc., Chroma Medicine, Inc., and Vertex Ventures HC.
He is also the Deputy Chairman-Supervisory Board at MorphoSys AG and the Vice Chairman at National Audubon Society, Inc. Additionally, he serves as a Director at Corbus Pharmaceuticals, Inc., BlackThorn Therapeutics, Inc., Tusk Therapeutics Ltd., and Droia Ventures.
In his former roles, Dr. Golumbeski served as the Chief Executive Officer at Nabriva Therapeutics GmbH from 2008 to 2009.
He was also the President & Director at GRAIL LLC from 2018 to 2019.
Furthermore, he held positions such as Chairman at Aura Biosciences, Inc. and BioSight Ltd., Director at Tizona Therapeutics, Inc., Pierce Biotechnology, Inc., Schwarz Pharma, Inc., EMD Pharmaceuticals, Inc., Acceleron Pharma, Inc., KSQ Therapeutics, Inc., and Enanta Pharmaceuticals, Inc., and Vice President & Director-Corporate Development at Schwarz Pharma, Inc. He was also the Senior Director-Licensing at EMD Pharmaceuticals, Inc. and the VP-Business Development, Licensing & Strategy at Novartis Oncology, Inc. Dr. Golumbeski's education includes a doctorate degree from the University of Wisconsin in 1985 and an undergraduate degree from the University of Virginia in 1979.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
01/04/2024 54 613 ( 0,11% ) 534 115 $ 30/04/2024
31/03/2024 8 000 ( 0,01% ) 108 640 $ 30/04/2024

Postes actifs de George Golumbeski

SociétésPosteDébut
MORPHOSYS AG Directeur/Membre du Conseil 17/05/2018
SAGE THERAPEUTICS, INC. Directeur/Membre du Conseil 23/01/2019
SHATTUCK LABS, INC. Président 22/10/2021
Directeur/Membre du Conseil -
Directeur/Membre du Conseil -
Président -
Droia Ventures Corporate Officer/Principal 01/10/2020
Directeur/Membre du Conseil 24/05/2022
Consultant / Advisor -
░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░ -
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░ ░░░░░░░░░░
Tous les postes actifs de George Golumbeski

Anciens postes connus de George Golumbeski

SociétésPosteFin
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de George Golumbeski

Formation de George Golumbeski

University of Wisconsin Doctorate Degree
University of Virginia Undergraduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de George Golumbeski

Relations

100 +

Relations au 1er degré

36

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées6
ENANTA PHARMACEUTICALS, INC.

Health Technology

MORPHOSYS AG

Health Technology

CORBUS PHARMACEUTICALS HOLDINGS, INC.

Health Technology

SHATTUCK LABS, INC.

Health Technology

AURA BIOSCIENCES, INC.

Health Technology

SAGE THERAPEUTICS, INC.

Health Technology

Entreprise privées27

Health Technology

Electronic Technology

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Commercial Services

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Commercial Services

Droia Ventures

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. George Golumbeski
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT